Merck KGaA's $3.5 Billion Acquisition of SpringWorks Therapeutics

Title

"German Pharmaceutical Giant Merck KGaA Finalizing $3.5 Billion SpringWorks Therapeutics Acquisition"

Keywords

• Pharmaceutical acquisition
• Rare cancer treatments
• Precision oncology
• $47 per share offer
• Strategic biotech buyout
• Desmoid tumors
• Neurofibromatosis
• OGSIVEO (nirogacestat)
• GOMEKLI (mirdametinib)

Key Facts

Merck KGaA, the German pharmaceutical company, has confirmed it is in late-stage discussions to acquire SpringWorks Therapeutics, a rare cancer biotech firm, for approximately $3.5 billion1. The proposed deal would value SpringWorks at $47 per share, representing a premium over recent trading prices24.

The acquisition talks, which were first rumored in February 2025, have now advanced to final stages with a potential agreement expected as early as Monday2. SpringWorks' stock jumped 9% following the announcement of these advanced negotiations2.

This strategic acquisition would give Merck KGaA control of SpringWorks' portfolio, which includes two recently approved drugs:
OGSIVEO (nirogacestat) for desmoid tumors and GOMEKLI (mirdametinib) for neurofibromatosis type 1-associated plexiform neurofibromas5. The move positions Merck KGaA to strengthen its presence in precision oncology and rare disease therapeutics, two high-growth areas in the pharmaceutical industry5.

While both companies have confirmed the discussions and pricing details, they have emphasized that no legally binding arrangement has yet been finalized23. The potential deal represents one of the largest pharmaceutical acquisitions of 2025 thus far5.

Sources:

1. https://www.fiercepharma.com/pharma/merck-kgaa-confirms-late-stage-talks-springworks-about-35b-buyout

2. https://www.biospace.com/business/springworks-surges-on-potential-3-5b-merck-kgaa-buyout

3. https://endpts.com/merck-kgaa-closes-in-on-springworks-deal-at-3-5b-price-point/

4. https://pharmaphorum.com/news/merck-puts-price-its-springworks-takeover-bid

5. https://www.ainvest.com/news/merck-3-5-billion-bet-springworks-strategic-leap-rare-disease-therapeutics-2504/